Expression and purification of E140 protein antigen fragments of Plasmodium vivax and Plasmodium berghei for serological assays
FEBS Open Bio · 2025
DOI: 10.1002/2211-5463.13939 ↗Kurz gefasst
Fachartikel in der Zeitschrift FEBS Open Bio, 2025. Verfasst von Rodolfo Ferreira Marques und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Hauptthemen laut MEDLINE: Plasmodium vivax, Plasmodium berghei, Antigens, Protozoan, Protozoan Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute of Allergy and Infectious Diseases, National Research, Development and Innovation Office, Fundação de Amparo à Pesquisa do Estado de São Paulo.
Abstract (Originalsprache)
Malaria, a life‐threatening disease caused by Plasmodium parasites, continues to pose a significant global health threat, with nearly 250 million infections and over 600 000 deaths reported annually by the WHO. Fighting malaria is particularly challenging partly due to the complex life cycle of the parasite. However, technological breakthroughs such as the development of the nucleoside‐modified mRNA lipid nanoparticle (mRNA‐LNP) vaccine platform, along with the discovery of novel conserved Plasmodium antigens such as the E140 protein, present new opportunities in malaria prevention. Importantly, production of recombinant proteins for malaria vaccine evaluation by serological assays often represents an additional hurdle because many Plasmodium proteins are complex and often contain transmembrane domains that make production and purification particularly difficult. This research protocol provides a step‐by‐step guide for the production and purification of P. berghei and P. vivax E140 protein fragments that can be used to test humoral immune responses against this novel malaria vaccine target. We demonstrate that the purified proteins can be successfully used in enzyme‐linked immunosorbent assay (ELISA) to evaluate antigen‐specific binding antibody responses in sera obtained from E140 mRNA‐LNP‐vaccinated mice. Therefore, these proteins can contribute to the development and evaluation of E140‐based malaria vaccines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
- Department of Parasitology, Institute of Biomedical Sciences, University of Sao Paulo, São Paulo, Brazil.
- Synthetic and Systems Biology Unit, Institute of Biochemistry, HUN-REN Biological Research Centre, Szeged, Hungary.
- National Laboratory for Biotechnology, Institute of Genetics, HUN-REN Biological Research Centre, Szeged, Hungary.
- ATGandCo Biotechnology Ltd, Mórahalom, Hungary.
ORCID-Profile: Edit Ábrahám, Hiromi Muramatsu, Zoltán Lipinszki
Förderung
- National Institute of Allergy and Infectious Diseases
- National Research, Development and Innovation Office
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- Magyar Tudományos Akadémia
- Nemzeti Kutatási Fejlesztési és Innovációs Hivatal
Zitieren
APA
Marques, R. F., Ábrahám, E., Muramatsu, H., Bargieri, D. Y., Pardi, N., & Lipinszki, Z. (2025). Expression and purification of E140 protein antigen fragments of Plasmodium vivax and Plasmodium berghei for serological assays. FEBS Open Bio. https://doi.org/10.1002/2211-5463.13939
Vancouver
Marques RF, Ábrahám E, Muramatsu H, Bargieri DY, Pardi N, Lipinszki Z. Expression and purification of E140 protein antigen fragments of Plasmodium vivax and Plasmodium berghei for serological assays. FEBS Open Bio. 2025. doi:10.1002/2211-5463.13939
BibTeX
@article{Marques2025,
author = {Marques, Rodolfo Ferreira and Ábrahám, Edit and Muramatsu, Hiromi and Bargieri, Daniel Youssef and Pardi, Norbert and Lipinszki, Zoltán},
title = {Expression and purification of E140 protein antigen fragments of Plasmodium vivax and Plasmodium berghei for serological assays},
journal = {FEBS Open Bio},
year = {2025},
doi = {10.1002/2211-5463.13939}
}
EUVIMED